Treatment with 5-aza and HDAC inhibitor trichostatin A (TSA) leads to increasing the BMPRII levels in SSc ECs; thus, it could potentially decrease endothelial cell apoptosis [129]. Here, HDAC9 is linked to systemic sclerosis.